Highlights Novonesis A/S

Equities

Delayed Nasdaq Copenhagen Other stock markets 10:59:34 2024-05-08 EDT			5-day change	1st Jan Change
418.4 ^DKK	+1.01%		+9.07%	+12.75%

05-03	Transcript : Novozymes A/S, Q1 2024 Sales/ Trading Statement Call, May 03, 2024
05-03	Novonesis Provides Sales Guidance for the Year 2024	CI

Novonesis Provides Sales Guidance for the Year 2024	05-03	CI
Final dividend	04-30	FA
Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023	04-30	CI
Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023	04-08	CI
Novonensis expects 2024 adjusted EBITDA margin of 35%	03-21	RE
Novonesis Provides Earnings Guidance for the Year 2024	03-21	CI
Biotalys, Novonesis Sign Deal to Advance Biofungicide Candidate Development	03-18	MT
Biotalys and Novonesis Announces Manufacturing and Commercialization Partnership for EVOCA NG	03-18	CI
FMC Partners With Novonesis in Canada for Biosolution Products	03-12	MT
Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West	03-07	CI
Novo Nordisk's controlling shareholder plans to invest about $35 billion by 2030	02-12	RE
Novozymes A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-08	CI
NOVOZYMES : Q4 23: destocking noise offsets recovery in other key segments	02-08
Novozymes, Chr. Hansen Complete Merger Settlement	02-02	MT
Novozymes Completes Merger with Chr. Hansen After Securing Final Registration, Issuing B Shares	01-29	MT
Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S.	01-28	CI
Novozymes, Chr. Hansen’s Proposed Merger Secures All Regulatory Approvals	01-26	MT
Novozymes, Chr. Hansen Merger Wins Korean Regulatory Nod	12-20	MT
Celadon Pharma raises GBP2.0 million via placing	12-12	AN
Novozymes-Chr. Hansen Merger Gets EU Nod After Proposed Asset Sale	12-12	MT

No results for this search

NOVOZYMES : Q4 23: destocking noise offsets recovery in other key segments

February 08, 2024 at 09:18 am